WARNING: This product is for research use only, not for human or veterinary use.
MedKoo CAT#: 205553
Description: NKTR-105 is a novel form of docetaxel that was developed using Nektar's advanced polymer technology platform. The compound belongs to the taxoid family and acts by disrupting the microtubular network in cells. It is being developed as an anti-neoplastic agent, and is the company's second oncology program in clinical development. In previous preclinical studies, NKTR-105 demonstrated superior antitumor activity with no neutropenia in multiple tumor models, indicating that NKTR-105 may enable sustained therapeutic levels of docetaxel without the myelosuppression that is a dose-limiting toxicity for this widely-used cancer therapy. (Sourced from http://ir.nektar.com/releasedetail.cfm?releaseid=378943)
MedKoo Cat#: 205553
NKTR-105 is not in stock, but may be available through custom synthesis. For cost-effective reason, minimum 1 gram order is requested. The product will be characterized by NMR, HPLC and MS analysis. Purity (HPLC) is usually >98%. CoA, QC data, MSDS will be provided when product is successfully made. The estimated lead time is 2-3 months. Please send email to email@example.com to inquire quote.
Synonym: NKTR105; NKTR-105; NKTR 105; docetaxel conjugate.
IUPAC/Chemical Name: NONE
The following data is based on the product molecular weight Batch specific molecular weights may vary from batch to batch due to the degree of hydration, which will affect the solvent volumes required to prepare stock solutions.
|Concentration / Solvent Volume / Mass||1 mg||5 mg||10 mg|
|1 mM||1.15 mL||5.76 mL||11.51 mL|
|5 mM||0.23 mL||1.15 mL||2.3 mL|
|10 mM||0.12 mL||0.58 mL||1.15 mL|
|50 mM||0.02 mL||0.12 mL||0.23 mL|
NKTR-105 is a polymer-conjugated docetaxel, currently being developed by Nektar. NKTR-105 is expected to improve the pharmacokinetic profile of the drug, resulting in prolonged exposure of the tumor to docetaxel and an improved time-concentration profile. Additionally, it is expected to enable higher therapeutic concentrations of the drug to be achieved and sustained over a longer period with a lower dose than the parent molecule, so as to potentially yield an enhanced therapeutic effect and improved tolerability. NKTR-105 is in a Phase 1 clinical trial in patients with certain types of solid tumors including hormone-refractory prostate cancer. Docetaxel is the only chemotherapeutic agent approved for use in five different cancer indications. It also could be explored as a therapy for breast, non-small cell lung, gastric, head and neck cancers. Each year, an estimated 3 million patients worldwide have been diagnosed with one of these types of cancer. (source: http://www.nektar.com/product_pipeline/oncology_nktr-105.html).
Current developer: Nektar Therapeutics, Inc.